Affiliation:
1. Siberian State Medical University of the Ministry of Health of the Russian Federation
Abstract
There is a universal trend towards increase of patients with chronic kidney disease by 7% on average. In the Russian Federation, the annual increase is even higher, at about 10%. The average age of patients receiving renal replacement therapy is 60 years in the Tomsk region and 56 years in Russia, which is relatively lower than in European countries and the United States. With increasing age of patients receiving dialysis treatment, a progressive increase in the incidence of secondary hyperparathyroidism is recorded. Mineral and bone disorders, hyperphosphatemia, hypercalcemia all lead to premature vascular calcification, increase the risk of cardiovascular complications and death. At the same time, elderly patients are characterized by an increase in risks immediately after the start of dialysis therapy. There is a global tendency towards increase in the target level of parathyroid hormone. Parathyroidectomy is recognized as a gold standard for treatment of drug-resistant hyperparathyroidism across the world. As the development of hyperplasia in the parathyroid glands does not proceed synchronously, instead progressing at different rates and in the selective glands, methods of local influence on the altered glands have recently been developed in order to gradually control secondary hyperparathyroidism. Alternative to the total parathyroidectomy are minimally invasive non-surgical methods, attractive due to a smaller number of complications, such as bleeding and paresis of the recurrent laryngeal nerve. Examples of minimally invasive methods are local injections of preparations of the active form of vitamin D, which lead to apoptosis of parathyroid gland cells instead of their destruction, and are safer in relation to surrounding tissues. This article presents current data on the prevalence of secondary hyperparathyroidism in chronic kidney disease. An analysis of clinical trials was carried out based on articles indexed in the Scopus database, the Russian Science Citation Index, PubMed and Web of Science.
Publisher
Cardiology Research Institute
Subject
Cardiology and Cardiovascular Medicine,Public Health, Environmental and Occupational Health,Radiology, Nuclear Medicine and imaging,Medicine (miscellaneous),Internal Medicine
Reference59 articles.
1. Lesovoy V.N., Andon'eva N.M., Valkovskaya T.L. Chronic kidney disease and hyperparathyroidism. Urology, andrology, nephrology. Materials of the scientific-practical conference. Kharkiv; 2016;48–49. (In Russ.).
2. Tomilina N.A., Andrusev A.M., Peregudova N.G., Shinkarev M.B. Replacement therapy for terminal chronic renal failure. Report according to the All-Russian Register of Renal Replacement Therapy of the Russian Dialysis Society. Part one. Nephrology and dialysis. 2017;19(4):1–95. (In Russ.).
3. Volgina G.V. Perepechennykh Yu.V. Parathyroid hormone is a universal uremic toxin. Nephrology and dialysis. 2000;29(1–2):75–78. (In Russ.).
4. Egshatyan L.V., Rozhinskaya L.Ya. Medical methods of correction of renal osteodystrophy. Osteoporosis and osteopathy. 2014;2:29–35. (In Russ.). DOI: 10.14341/osteo2014229-35.
5. Shtandel V.S., Volgina G.V., Balkarova O.V., Lovchinsky E.V. Calcimimetics – a new stage in the treatment of hyperparathyroidism. Attending doctor. 2011;3:1–4. (In Russ.).